Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 113 | 1 | 114 | +2 |
| Shares | 94.4M | 9.56M | 94.6M | +9.69M (+11.4%) |
| Value | $94.2M | $9.53M | $85.6M | +$966.7K (+1.1%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (9)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 9,919,800 | $8.98M | 0.00% |
| Gsa Capital Partners LLP | 93,032 | $84.0K | 0.01% |
| SG Americas Securities, LLC | 50,920 | $46.0K | 0.00% |
| Two Sigma Securities, LLC | 13,941 | $12.6K | 0.00% |
| Engineers Gate Manager LP | 11,458 | $10.4K | 0.00% |
| Trust Co of Vermont | 1,553 | $1.41K | 0.00% |
| Group One Trading, L.P. | 745 | $674 | 0.00% |
| Capital Performance Advisors LLP | 163 | $148 | 0.00% |
| Sterling Capital Management LLC | 150 | $136 | 0.00% |
Sold out (7)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Millennium Management LLC | 168,978 | $168.5K |
| Virtu Financial LLC | 78,454 | $78.0K |
| MetLife Investment Management | 78,181 | $78.0K |
| Qube Research & Technologies Ltd | 68,286 | $68.1K |
| XTX Topco Ltd | 61,515 | $61.3K |
| Squarepoint Ops LLC | 44,307 | $44.2K |
| Crewe Advisors LLC | 1,016 | $1.01K |
Not filed for Q3 2024 yet (1)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 9,559,466 | $9.53M |